Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit plenty of to tolerate FCR therapy, should still be great candidates with the latter, While using the gain currently being that this procedure might be finished in six months even though ibrutinib should be taken indefinitely. This selection will be especially precious for